6Kiby R S. The natural history of benign prostatic hyperplasia:What have we learned in the last decade? J Urol, 2000, 56: 3-6.
7Willam K O H, Kantoff W P. Management of hormone refractory prostate cancer: current standrds and future prospects. J Urol, 1998, 160: 1220-1229.
8Leo M E, Bilharta D L, Bergstralh E J, et al. Prostate specfte antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indictor of hormonally treated stage D2 prostate cancer: is it always an accurate indictor of disease status. J Urol, 1991, 145:802-804.
9Matzkin H, Eber P, Todd B, et al. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostate cancer. Cancer,1992, 70: 2302-2308.
10Stamey T A, Kabalin J N, Ferrari M, et al. Prostate specific antigen in the diagnosis and treatment of adeno carcinoma of the prostate Ⅳ anti-androgen treated patients. J Urol, 1989, 141: 1088-1090.
9SHIN SY, LEE JY, LEE E, et al. Protective effect of vascular endothelial growth factor (VEGF) in frozen-thawed granulosa cells is mediated by inhibition of apoptosis[J]. Eur J Obstet Gynecol Rep rod Biol, 2006, 125(5) :233-238.
10JOSEPH E. OESTERLING. LHRH Agonists A Nonsurgical Treatment for Benign Prostatic Hyperplasia[J]. JOA, 1991,12 (6) :381-388.
